Navigation Links
Orbsen Therapeutics Moves Into New Headquarters in Galway, Ireland
Date:4/4/2019

Orbsen Therapeutics, a biotechnology company focused on the discovery, development and commercialization of first-in-class stromal cell immunotherapies, announced it will move its base of operations from the National University of Ireland (NUI) Galway campus to become the anchor tenant at the University’s newly created biotechnology park in Galway, Ireland.

“With four clinical trials in full swing and the closing of additional funding rounds to support the development of our novel therapies, we simply needed additional space to accommodate our increasing staff and prepare for our next phase of growth,” said Dr. Larry Couture, CEO of Orbsen Therapeutics. “The move reflects the progress we are making in the development of our therapies, bringing them one step closer to addressing some of today’s most challenging diseases.”

Orbsen Therapeutics’ new global headquarters will combine laboratory and office space on two levels of the park’s inaugural three-story building.

“We are delighted Orbsen Therapeutics was set in motion at NUI Galway and will continue its exciting expansion here in our region,” said David Murphy, Director of the Innovation Office at NUI Galway. “Generating and supporting regional development is central to the University’s strategy. Currently, NUI Galway supports more than 40 companies on campus. Extending the University’s incubation eco-system will allow us to amplify efforts and enable even more start-up companies to innovate and grow.”  

Orbsen’s proprietary ORBCEL™ immunotherapy yields nearly 100 percent pure stromal cells, a significant increase in purity when compared to first generation stromal cell therapies.

Orbsen currently is enrolling and treating patients in four clinical trials to assess ORBCEL’s safety and efficacy in the prevention and treatment of diabetic kidney disease, non-healing diabetic foot ulcers, moderate to severe acute respiratory distress syndrome (ARDS) and in patients with primary sclerosis cholangitis (PSC) and autoimmune hepatitis. A fifth trial is pending for patients with several auto-immune disorders.

Orbsen’s new headquarters will be the hub of operations to coordinate research, operations, product development and clinical development.

About Orbsen Therapeutics

Orbsen Therapeutics, Ltd. is a leading company in the development of cellular immunotherapies across four immune-mediated inflammatory conditions. Founded in 2006, Orbsen Therapeutics Ltd., is a privately held company led by global leaders in the field of cellular immunotherapy. The company, which spun-out from Ireland’s Regenerative Medicine Institute at the National University or Ireland Galway, has developed proprietary technologies that enables the isolation of a well characterized population of pure stromal cells from human tissues which, once isolated, can be expanded and frozen to generate multiple doses of a high-margin, “off the shelf” therapeutic product.

For more information visit: http://www.orbsentherapeutics.com

Read the full story at https://www.prweb.com/releases/orbsen_therapeutics_moves_into_new_headquarters_in_galway_ireland/prweb16211996.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related biology news :

1. Orbsen Therapeutics' NEPHSTROM Clinical Trial Underway at Four European Union Locations
2. Nativis Announces Name Change To EMulate Therapeutics, Inc.
3. uBiome Receives Patent for Microbiome-Derived Diagnostics and Therapeutics for Immune-Microbial Dysfunction
4. RoosterBio Inc. and Tissue Regeneration Therapeutics Inc. Announce Alliance Around Scale-up Manufacturing of Umbilical Cord Tissue Perivascular Cell Technology
5. Cybrexa Therapeutics Expands Scientific Advisory Board Ahead of IND Filing
6. Genedata Announces Aptevo Therapeutics Deploys Genedata Biologics to Streamline Cancer Immunotherapy R&D
7. Spero Therapeutics Acquires Next Generation Antibacterial Candidates from Pro Bono Bio for Treatment of Multidrug-Resistant, Gram-Negative Infections
8. MicroRNA: An Insight to miRNA-based microarrays, diagnostics and therapeutics Overview, Cambridge Healthtech Advisors
9. Eureka Therapeutics raises $21 million in series c to expand cancer immunotherapy pipeline
10. Study shows Hera Therapeutics compound combats HPV types that cause most cervical cancer
11. Human Longevity, Inc. and Celgene Cellular Therapeutics Sign License Agreement to Develop and Commercialize Placental Stem Cell Population, PSC-100 for Multiple Therapeutic Applications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/4/2019)... ... April 02, 2019 , ... Researchers from Ambry Genetics ... RNA genetic testing (RGT), as a supplement to DNA genetic testing, improves variant ... poster, is one of 13 presentations at the 2019 American College of Medical ...
(Date:4/1/2019)... ... April 01, 2019 , ... ... Characterizing Skin Related Conditions” by the US Patent and Trademark Office on January ... an invention by uBiome collaborators Dr. Zachary Apte, Dr. Daniel Almonacid, Dr. ...
(Date:3/29/2019)... ... ... In the development of biosimilars, the broad definition of the similarity concept in ... several manufacturers have been successful and numerous follow-on biologics are approved in the US ... analytical similarity is achieved in biosimilars based on recently approved products in the US. ...
Breaking Biology News(10 mins):
(Date:4/8/2019)... Utah and BOSTON (PRWEB) , ... April 08, ... ... delivering cloud-based enterprise-class unified communications and collaboration solutions, announced today the launch of ... integration to an unprecedented range of business and contact-orientated applications while using CT ...
(Date:4/8/2019)... (PRWEB) , ... April 09, 2019 , ... ... disease, the innovative non-profit research center Chan Zuckerberg Biohub (CZ Biohub) has chosen ... of antibody repertoires is part of CZ Biohub’s efforts to establish new approaches ...
(Date:4/4/2019)... (PRWEB) , ... April 03, 2019 , ... ... together through intimate off-the-record collaboration and dialogue, today announces its Boston CEO conference ... offers insights into the industry’s challenges and opportunities with high-level panels and discussions ...
(Date:3/27/2019)... ... ... A leader in the field of Regenerative Veterinary Medicine, VetStem Biopharma has ... Canada since 2004. The primary indications for VetStem Regenerative Cell Therapy are ... and horse. Recently, VetStem teamed up with the world-renowned San Diego Zoo to ...
Breaking Biology Technology: